The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology

Value in Health

Volumn 13, Issue 6, 2010, Pages 712-719

  Tan, Siok Swan ^a   Van Gils, Chantal W M ^a   Franken, Margreet G ^a   Hakkaart Van Roijen, Leona ^a   Uyl De Groot, Carin A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

daycare treatment; hematology; inpatient hospital day; oncology; outpatient visit; reference price; unit cost

Indexed keywords

ARTICLE; CONSULTATION; COST UTILITY ANALYSIS; DAY CARE; DAY HOSPITAL; GENERAL HOSPITAL; HEALTH CARE COST; HEMATOLOGY; HOSPITAL CARE; HOSPITAL COST; HUMAN; MONEY; NETHERLANDS; ONCOLOGY; OUTPATIENT CARE; PREDICTOR VARIABLE; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

EID: 77956368910     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00740.x     Document Type: Article

References (23)

1. Groot MT, Huijgens PC, Uyl-de Groot CA. Introduction of expensive pharmaceuticals in haemato-oncology in the Netherlands and throughout Europe. Eur J Hosp Pharm Pract 2006 12 : 30 6.
2. Rodenburg-van Dieten HEM. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie. Diemen : College voor zorgverzekeringen, 2005.
3. Uyl-de Groot CA, Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005 17 : 392 396.
4. Dumarcet N. [Activity tarification and national guidelines for the proper use of expensive and innovative drugs in internal medicine]. Rev Med Interne 2008 29 : 84 6.
5. Jefford M, Savulescu J, Thomson J, et al. Medical paternalism and expensive unsubsidised drugs. BMJ 2005 331 : 1075 1077.
6. Drummond M. Methods for the Economic Evaluation of Health Care Programmes. New York : Oxford University Press, 2005.
7. Oostenbrink JB, Buijs-Van der Woude T, van Agthoven M, et al. Unit costs of inpatient hospital days. Pharmacoeconomics 2003 21 : 263 271.
8. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002 20 : 443 454.
9. Adam T, Evans DB. Determinants of variation in the cost of inpatient stays versus outpatient visits in hospitals: a multi-country analysis. Soc Sci Med 2006 63 : 1700 1710.
10. Hale JP, Cohen DR, Maughan TS, Stephens RJ. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br J Cancer 2002 86 : 1684 1690.
11. Hieke K, Kleeberg UR, Stauch M, Grothey A. Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ 2004 5 : 270 273.
12. Maroun J, Asche C, Romeyer F, et al. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Pharmacoeconomics 2003 21 : 1039 1051.
13. Ritzwoller DP, Goodman MJ, Maciosek MV, et al. Creating standard cost measures across integrated health care delivery systems. J Natl Cancer Inst Monogr 2005 35 : 80 7.
14. Coutet J, Limat S, Voillat L, et al. Economic impact of outpatient chemotherapy in multiple myeloma. Bull Cancer 2004 91 : 729 734.
15. Friedman BS, Wong HS, Steiner CA. Renewed growth in hospital inpatient cost since 1998: variation across metropolitan areas and leading clinical conditions. Am J Manag Care 2006 12 : 157 166.
16. Tan SS, Rutten FF, van Ineveld BM, et al. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ 2009 10 : 39 45.
17. Centraal Bureau voor de Statistiek. Statline cited Statline 2009]; Available from: http://statline.cbs.nl [Accessed January 1, 2009].
18. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007 370 : 135 142.
19. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase III study on the effect of thalidomide combined with adriamycin, dexamethasone (TAD), and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010 115 : 1113 1120.
20. van Agthoven M, Segeren CM, Buijt I, et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 2004 40 : 1159 1169.
21. Ward SE, Kaltenthaler E, Cowan J, et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006 95 : 27 34.
22. Wordsworth S, Ludbrook A, Caskey F, Macleod A. Collecting unit cost data in multicentre studies. Creating comparable methods. Eur J Health Econ 2005 6 : 38 44.
23. Tan SS, van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the allocation of overhead and capital costs to hospital services. Value Health 2008 12 : 530 535.